Header Logo

Connection

Douglas Golenbock to Ligands

This is a "connection" page, showing publications Douglas Golenbock has written about Ligands.
Connection Strength

0.391
  1. Latz E, Verma A, Visintin A, Gong M, Sirois CM, Klein DC, Monks BG, McKnight CJ, Lamphier MS, Duprex WP, Espevik T, Golenbock DT. Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol. 2007 Jul; 8(7):772-9.
    View in: PubMed
    Score: 0.065
  2. Fitzgerald KA, Golenbock DT. Immunology. The shape of things to come. Science. 2007 Jun 15; 316(5831):1574-6.
    View in: PubMed
    Score: 0.065
  3. Schoenemeyer A, Barnes BJ, Mancl ME, Latz E, Goutagny N, Pitha PM, Fitzgerald KA, Golenbock DT. The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J Biol Chem. 2005 Apr 29; 280(17):17005-12.
    View in: PubMed
    Score: 0.055
  4. Golenbock DT, Fenton MJ. Extolling the diversity of bacterial endotoxins. Nat Immunol. 2001 Apr; 2(4):286-8.
    View in: PubMed
    Score: 0.042
  5. Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, Fenton MJ, Oikawa M, Qureshi N, Monks B, Finberg RW, Ingalls RR, Golenbock DT. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest. 2000 Feb; 105(4):497-504.
    View in: PubMed
    Score: 0.039
  6. Langjahr P, D?az-Jim?nez D, De la Fuente M, Rubio E, Golenbock D, Bronfman FC, Quera R, Gonz?lez MJ, Hermoso MA. Metalloproteinase-dependent TLR2 ectodomain shedding is involved in soluble toll-like receptor 2 (sTLR2) production. PLoS One. 2014; 9(12):e104624.
    View in: PubMed
    Score: 0.027
  7. Harris J, Hartman M, Roche C, Zeng SG, O'Shea A, Sharp FA, Lambe EM, Creagh EM, Golenbock DT, Tschopp J, Kornfeld H, Fitzgerald KA, Lavelle EC. Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation. J Biol Chem. 2011 Mar 18; 286(11):9587-97.
    View in: PubMed
    Score: 0.021
  8. Seimon TA, Obstfeld A, Moore KJ, Golenbock DT, Tabas I. Combinatorial pattern recognition receptor signaling alters the balance of life and death in macrophages. Proc Natl Acad Sci U S A. 2006 Dec 26; 103(52):19794-9.
    View in: PubMed
    Score: 0.016
  9. Massari P, Visintin A, Gunawardana J, Halmen KA, King CA, Golenbock DT, Wetzler LM. Meningococcal porin PorB binds to TLR2 and requires TLR1 for signaling. J Immunol. 2006 Feb 15; 176(4):2373-80.
    View in: PubMed
    Score: 0.015
  10. Santos-Sierra S, Golenbock DT, Henneke P. Toll-like receptor-dependent discrimination of streptococci. J Endotoxin Res. 2006; 12(5):307-12.
    View in: PubMed
    Score: 0.015
  11. Romics L, Dolganiuc A, Velayudham A, Kodys K, Mandrekar P, Golenbock D, Kurt-Jones E, Szabo G. Toll-like receptor 2 mediates inflammatory cytokine induction but not sensitization for liver injury by Propioni- bacterium acnes. J Leukoc Biol. 2005 Dec; 78(6):1255-64.
    View in: PubMed
    Score: 0.014
  12. Means TK, Golenbock DT, Fenton MJ. The biology of Toll-like receptors. Cytokine Growth Factor Rev. 2000 Sep; 11(3):219-32.
    View in: PubMed
    Score: 0.010
  13. Means TK, Lien E, Yoshimura A, Wang S, Golenbock DT, Fenton MJ. The CD14 ligands lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors. J Immunol. 1999 Dec 15; 163(12):6748-55.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.